Axcella Health, which is developing therapeutics and dietary products for amino acid dysregulation, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2008 and plans to list on the Nasdaq under the symbol AXLA. Axcella Health filed confidentially on January 28, 2019. Goldman Sachs, J.P. Morgan and SVB Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.
